BPC-157

BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) and a molecular weight of 1,419 Daltons. Also known as Body Protection Compound-157, it is derived from a larger protective protein naturally present in human gastric juice, where it plays a role in maintaining mucosal integrity throughout the gastrointestinal tract. ⁽⁵⁾

What sets BPC-157 apart from most research peptides is its remarkable stability. Unlike the majority of peptides that degrade rapidly in acidic environments, BPC-157 remains structurally intact in gastric juice at pH levels as low as 1.0. ⁽⁵⁾ This resistance to acid-mediated and enzymatic breakdown is one reason it has attracted significant attention in the research community, particularly for studies involving oral administration. The compound does not require a carrier molecule for delivery, which considerably simplifies experimental protocols.

Since its initial characterization (also characterized in US literature) in the early 1990s, BPC-157 has been the subject of extensive preclinical investigation. A 2025 systematic review published in the HSS Journal identified 544 articles from 1993 to 2024, of which 36 met the inclusion criteria for detailed analysis across musculoskeletal applications alone. ⁽¹⁾ Beyond orthopedic research, hundreds of additional studies have examined its effects on gastrointestinal tissue, the nervous system, vascular function, and organ protection. The peptide has also progressed to Phase II clinical trials for inflammatory bowel disease under the pharmaceutical designation PL-14736. ⁽⁷⁾

Healius supplies BPC-157 as a lyophilized (also referred to as lyophilized in US research literature) powder in 5mg and 10mg vials, intended strictly for laboratory and research applications.

BPC-157 promotes healing through multiple overlapping molecular pathways rather than acting on a single receptor or enzyme. Researchers have described this broad activity as pleiotropic cytoprotection, reflecting the peptide’s ability to simultaneously support tissue repair, reduce inflammation, and protect against further damage. ^(1,9)

One of the most well-documented actions involves upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and promotion of angiogenesis through the Akt-eNOS signaling axis. ⁽¹⁾ In practical terms, this means BPC-157 promotes the formation of new blood vessels at sites of tissue damage, a process that is critical for delivering oxygen and nutrients required for repair. This is particularly relevant in tissues with poor blood supply, such as tendons and ligaments, where healing is notoriously slow. ⁽²⁾

At the cellular level, BPC-157 has been shown to upregulate growth hormone receptor expression in tendon fibroblasts in a dose- and time-dependent manner. ⁽³⁾ Research published in Molecules (Chang et al., 2014) demonstrated that this increase in growth hormone receptor density potentiated the proliferative effects of growth hormone on tendon cells, with downstream activation of the Janus kinase 2 (JAK-2) signaling pathway. ⁽³⁾ The peptide also activates the FAK-paxillin pathway, which governs cell migration, a fundamental process in wound closure and tissue remodeling. ⁽⁴⁾

BPC-157 modulates the nitric oxide (NO) system in distinct ways. Rather than simply increasing or decreasing NO production, it appears to normalize NO levels in response to physiological context. ⁽¹⁰⁾ This interaction with the NO system underpins many of its observed effects on blood vessel function, inflammation, and tissue protection. The peptide also stimulates the early growth response 1 (Egr-1) gene, which is responsible for cytokine and growth factor generation as well as early extracellular matrix formation, and its repressor NAB2 (nerve growth factor 1-A binding protein-2). ⁽⁶⁾ Additionally, ERK1/2 signaling activation facilitates endothelial and muscle repair processes. ⁽¹⁾

The anti-inflammatory effects of BPC-157 involve reducing inflammatory cytokine levels and promoting repair pathways. ⁽¹⁾ This dual action, reducing damage while simultaneously accelerating recovery, distinguishes the peptide from agents that only address one side of the healing equation.

Musculoskeletal tissue repair represents the most extensively studied application of BPC-157 in the published literature. The 2025 systematic review by Vasireddi et al., published in HSS Journal, analyzed 36 studies spanning three decades and concluded that BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bony injury models in preclinical settings. ⁽¹⁾

In tendon research, studies on transected rat Achilles tendons have consistently shown that BPC-157-treated subjects demonstrate significantly accelerated healing compared to controls. Biomechanical testing revealed increased load to tendon failure in treated groups, while the Achilles Functional Index (AFI) confirmed superior functional recovery over 14-day observation periods. ⁽⁴⁾ At the cellular level, BPC-157 promoted fibroblast outgrowth from tendon explants, improved fibroblast survival under oxidative stress, and enhanced cell migration in a dose-dependent manner, as documented by Chang et al.  ⁽²⁰¹¹⁾ in the Journal of Applied Physiology. ⁽⁴⁾

Ligament research has produced similarly consistent findings. In medial collateral ligament (MCL) transection models, BPC-157 treatment was associated with reduced joint instability, decreased post-injury contracture, and restoration of biomechanical properties. ⁽⁸⁾ Cerovecki et al.  ⁽²⁰¹⁰⁾ reported in the Journal of Orthopedic Research that ligament healing was significantly improved at both macroscopic and microscopic levels. ⁽⁸⁾

Muscle injury models, including complete muscle transection, have demonstrated that BPC-157 accelerates the recovery of muscle function and structure. ⁽¹⁾ Biochemical markers, along with macroscopic and microscopic observations, confirmed improved healing trajectories in treated subjects. The peptide’s effects on muscle extend beyond traumatic injury to include protection against systemic insults such as hyperkalemia and hypermagnesaemia. ⁽²⁾

Perhaps the most compelling human data comes from a retrospective study examining intra-articular knee injections. Of 12 patients with chronic, unspecified knee pain who received BPC-157 injections (2 cc of 2000 mcg/mL solution), 7 reported subjective symptom improvement lasting more than 6 months. ⁽¹⁾ A follow-up assessment of 16 patients receiving BPC-157 or BPC-157 combined with TB4 found that 14 (87.5%) experienced significant pain relief. ⁽¹⁾ While these results come from small, uncontrolled studies with acknowledged limitations, they represent the earliest direct human evidence in an orthopedic context.

For researchers investigating musculoskeletal repair pathways, BPC-157 is a well-characterized compound with over three decades of preclinical data supporting its role in the recovery of tendon, ligament, muscle, and bone tissue.

The gastrointestinal tract is where BPC-157’s story begins. Isolated from a protective protein found in human gastric juice, the peptide has been extensively researched for its effects on gut mucosal integrity, ulcer healing, and inflammatory bowel conditions. ⁽⁵⁾ This body of research is substantial enough that BPC-157 has advanced to Phase II clinical trials for inflammatory bowel disease under the designation PL-14736. ⁽⁷⁾

Preclinical studies have demonstrated BPC-157’s protective and healing effects across virtually every model of gastrointestinal injury examined. Research by Sikiric et al., extensively reviewed in Current Pharmaceutical Design ⁽²⁰¹¹⁾, showed that the peptide counteracted NSAID-induced gastrointestinal lesions, prevented and reversed alcohol-induced gastric damage, and promoted healing of gastric and duodenal ulcers. ⁽⁵⁾ Importantly, BPC-157 was effective both when administered before the injury (prophylactically) and after damage had already occurred (therapeutically).

In intestinal anastomosis models, BPC-157 significantly improved healing outcomes. ⁽⁵⁾ Edema was markedly reduced from day one, granulocyte infiltration decreased, and granulation tissue, reticulin, and collagen formation substantially increased, leading to enhanced epithelisation. Biomechanical testing confirmed that treated anastomoses could sustain higher volumes and pressures without leaking.

The peptide’s effects on fistula healing are particularly notable. In persistent colo-rectal fistula models, BPC-157 accelerated the closure of both colonic and skin defects when administered either parenterally or orally in drinking water. ⁽⁵⁾ Remarkably, fistula closure was achieved even when treatment was delayed by one month after the initial injury.

Short bowel syndrome research demonstrated that BPC-157 triggered balanced intestinal adaptation across all three wall layers, with increases in villus height, crypt depth, and thickness of the circular muscular layer. ⁽¹⁰⁾ Treated subjects achieved constant weight gain above preoperative values immediately upon commencing therapy. The peptide also increased the survival rate of cultured enteric neurons. It promoted proliferation of enteric glial cells, suggesting effects that extend beyond simple tissue repair to support the gut’s intrinsic nervous system. ⁽¹⁰⁾

A 2024 pilot study by Lee et al. investigated intravesicular (bladder) injections of BPC-157 in 12 individuals with moderate-to-severe interstitial cystitis who had not responded to standard treatment. The results showed 80-100% resolution of symptoms at six weeks post-treatment. ⁽¹¹⁾

A 2025 presentation at the American College of Gastroenterology further reinforced these findings, concluding that BPC-157 shows promise for mucosal protection, wound healing, inflammatory bowel disease, and mitigation of NSAID-induced gastrointestinal injury based on the preclinical evidence to date. ⁽¹⁶⁾

1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopedic Sports Medicine: A Systematic Review. HSS Journal. 2025. doi:10.1177/15563316251355551

2. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159.

3. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(12):19066-19077.

4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.

5. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in the gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.

6. Sikiric P, Rucman R, Turkovic B, et al. Brain-Gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.

7. Sikiric P, Seiwerth S, Grabarevic Z, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012;19(1):126-132.

8. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopedic Research. 2010;28(9):1155-1161.

9. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals. 2025;18(2):185.

10. Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167.

11. Lee R, Rashed H, Engel A, Burgess G. Intravesicular BPC-157 for interstitial cystitis: pilot study. 2024. (Referenced in PMC narrative review, 2025).

12. Lee R, Burgess G. Intravenous BPC-157 safety and pharmacokinetics in healthy adults: pilot study. 2025. (Referenced in PMC narrative review, 2025).

13. Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001;27(8):817-827.

14. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns. 2003;29(4):323-334.

15. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196.

16. Oral Peptide BPC-157: An Emerging Adjunct to Gastrointestinal Therapy. American College of Gastroenterology Annual Meeting Abstract S808. 2025.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.